Trials / Not Yet Recruiting
Not Yet RecruitingNCT06819514
The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
A Phase 1/2, Multicenter, Open-label,Dose-escalation Study to Evaluate the Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Guangzhou Jiayin Biotech Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase 1/2, multicenter, open-label, Dose-escalation study to evaluate the safety and efficacy of intravenous EXG110 in patients with Fabry disease
Detailed description
Phase 1: Dose -escalation，2 Groups Phase 2: Dose- expansion，1 Group
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EXG110 Injection | EXG110 Injection is gene therapy for Fabry Disease , uses a proprietary AAV capsid with improved liver and muscle specificity. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2028-03-15
- Completion
- 2028-03-15
- First posted
- 2025-02-11
- Last updated
- 2025-02-11
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06819514. Inclusion in this directory is not an endorsement.